ISRCTN47380065已完成1 期
A Cancer Research UK Phase I trial of olaparib (AZD2281), an oral PARP Inhibitor, in combination with extended lowdose oral temozolomide in patients with relapsed glioblastoma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Histological proven glioblastoma (World Health Organisation[WHO] Grade 4).
- •2. Radiological diagnosis of recurrent or progressive disease according to RANO criteria, which is suitable for palliative resection.
- •3. Patients should have enough resectable tumour tissue for sampling requirements in the opinion of the neurosurgeon.
- •4. Prior 1st line treatment with radical radiotherapy, or chemoradiation followed by adjuvant chemotherapy (no prior
- •chemotherapy for recurrent disease is allowed).
- •5. Aged between 18 and 70 years.
- •6. Life expectancy > 12 weeks
- •7. WHO performance status of 02
- •8. Haematological and biochemical indices within the ranges shown below. These measurements must be performed within one week before the patient goes on study.
- •Haemoglobin (Hb) = 9.0 g/dL
- •Absolute neutrophil count (ANC) = 1.5 x 109/L
- •Platelet count = 100 x 109/L
- •Serum bilirubin = 1.5 x upper limit of normal (ULN)
- •ALT or AST = 2.5 x ULN
- •Either: Calculated creatinine clearance = 50 mL/min Or: Isotope clearance measurement = 50 mL/min (uncorrected)
- •9. Ability to swallow and retain oral medications.
- •10. Written (signed and dated) informed consent and be capable of cooperatingwith treatment, scans and followup
排除标准
- •1. Radiotherapy, endocrine therapy or immunotherapy during the previous 12 weeks before treatment, or chemotherapy during the 4 weeks before treatment.
- •2. Any previous treatment with a PARP inhibitor, including olaparib.
- •3. Ongoing toxic manifestations of previous treatments. Exceptions to this are alopecia or Grade 1 toxicities, which in the opinion of the Investigator and the Drug Development Office (DDO) should not exclude the patient.
- •4. Change to systemic steroids dose within the five days prior to enrolment (ie. must be on a stable dose at time of
- •enrolment).
- •5. Ability to become pregnant (or already pregnant or lactating). However, those female patients who have a negative serum or urine pregnancy test before enrolment and agree to use two highly effective forms of contraception (oral, injected or implanted hormonal contraception and condom, have a intrauterine
- •device and condom, diaphragm with spermicidal gel and condom) for four weeks before entering the trial, during the trial and for six months afterwards are
- •considered eligible.
- •6. Male patients with partners of childbearing potential (unless they agree to take measures not to father children by using one form of highly effective contraception [condom plus spermicide] during the trial and for six months afterwards). Men with pregnant or lactating partners should be advised to use barrier method contraception (for example, condom plus spermicidal gel) to prevent exposure to the foetus or neonate.
- •7. Major thoracic or abdominal surgery from which the patient has not yet recovered.
- •8. At high medical risk because of nonmalignant systemic disease including active uncontrolled infection.
- •9. Known to be serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV).
- •10. Concurrent congestive heart failure, prior history of class III/ IV cardiac disease (New York Heart Association [NYHA]
- •refer to Appendix 3), prior history of cardiac ischaemia or prior history of cardiac arrhythmia within the previous 12 months.
- •11. Patients with pacemakers, a history of previous heart surgery, any major surgery in the preceding six weeks, metal fragments in their eyes, shrapnel or bullet injuries are excluded (on the basis of their unsuitability to undergo MRI scans). Patients with metal implants or tattoos should be discussed with MRI staff.
- •12. Grand mal seizures occurring = 3 times per week over the past month.
- •13. Patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
- •14. Patients taking drugs known to be potent inhibitors or inducers of CYP3A4 including phenytoin, carbamazepine and phenobarbitone which cannot be stopped for the duration of the trial.
- •15. Immunisations with live vaccines received within the previous four weeks (or expected to receive during the trial and up to at least six months after receiving last study treatment). Including BCG and yellow fever.
- •16. Known hypersensitivity to any of the components of olaparib.
- •17. Known hypersensitivity to temozolomide (TMZ), or to any of its components, or to dacarbazine (DTIC) (Stage 2 only).
- •18. Known lactose intoleran
研究者
相似试验
进行中（未招募）
1 期
Trial comparing weekly chemotherapy with oral olaparib or olaparib and cediranib in women with relapsed ovarian cancer.BRCA mutated platinum-resistant ovarian cancerMedDRA version: 21.1Level: LLTClassification code 10033131Term: Ovarian carcinomaSystem Organ Class: 100000004864EUCTR2016-000559-28-GBniversity of Oxford138
已完成
1 期
Olaparib and Temozolomide in Treating Patients With Relapsed GlioblastomaBrain and Central Nervous System TumorsNCT01390571Cancer Research UK34
进行中（未招募）
1 期
A Phase II Clinical Trial to analyse the efficacy and safety of the treatment with Olaparib in patients diagnosed of metastatic or locally advanced breast cancer who show methylation in the promoter of the genes BRCA1 and/or 2 (COMETA-Breast study).Patients with advanced triple negative breast cancer (TNBC) with BRCA1 and/or BRCA2 promoter methylation assessed in DNA from metastatic lesions and absence of BRCA1 and 2 germline mutations.MedDRA version: 19.0Level: PTClassification code 10075566Term: Triple negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001407-23-ESGEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)
进行中（未招募）
不适用
STOMP: Small cell lung cancer Trial of Olaparib (AZD2281) as Maintenance Programme: a randomised, double blind, multicentre phase II trial - STOMP: SCLC Trial of Olaparib (AZD2281) as Maintenance Programme.Small cell lung cancerEUCTR2010-021165-76-GBSheffield Teaching Hospitals NHS Foundation Trust222
尚未招募
2 期
A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancercancer of the ovary that has recurredrecurrent ovarian cancer10038594NL-OMON53750ordic Society of Gynaecological Oncology - Clinical Trial Unit, Department of Oncology, 9431, Rigshospitalet, Copenhagen University Hospital20